SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0000950142-16-003797
Filing Date
2016-05-27
Accepted
2016-05-27 16:15:48
Documents
4
Group Members
AISLING CAPITAL III, LPAISLING CAPITAL PARTNERS III LLCAISLING CAPITAL PARTNERS III, LPANDREW SCHIFFDENNIS PURCELLSTEVEN ELMS

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D eh1600646_sc13d-loxo.htm SC 13D 175268
2 EXHIBIT 99.1 eh1600646_ex9901.htm EX-99.1 26862
3 EXHIBIT 99.2 eh1600646_ex9902.htm EX-99.2 23796
4 EXHIBIT 99.4 eh1600646_ex9904.htm EX-99.4 25922
  Complete submission text file 0000950142-16-003797.txt   253507
Mailing Address 888 Seventh Avenue, 30th Fl New York NY 10106
Business Address 888 Seventh Avenue, 30th Fl New York NY 10106 212-651-6380
AISLING CAPITAL III LP (Filed by) CIK: 0001444717 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE
Type: SC 13D

Mailing Address 281 TRESSER BOULEVARD, 9TH FLOOR STAMFORD CT 06901
Business Address 281 TRESSER BOULEVARD, 9TH FLOOR STAMFORD CT 06901 203-653-3880
Loxo Oncology, Inc. (Subject) CIK: 0001581720 (see all company filings)

IRS No.: 462996673 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-88267 | Film No.: 161682582
SIC: 2834 Pharmaceutical Preparations